These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31437703)

  • 1. Normalization of EEG in depression after antidepressant treatment with sertraline? A preliminary report.
    van der Vinne N; Vollebregt MA; Boutros NN; Fallahpour K; van Putten MJAM; Arns M
    J Affect Disord; 2019 Dec; 259():67-72. PubMed ID: 31437703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EEG Abnormalities Are Associated With Poorer Depressive Symptom Outcomes With Escitalopram and Venlafaxine-XR, but Not Sertraline: Results From the Multicenter Randomized iSPOT-D Study.
    Arns M; Gordon E; Boutros NN
    Clin EEG Neurosci; 2017 Jan; 48(1):33-40. PubMed ID: 26674366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a Machine Learning Model Based on Pretreatment Symptoms and Electroencephalographic Features to Predict Outcomes of Antidepressant Treatment in Adults With Depression: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Rajpurkar P; Yang J; Dass N; Vale V; Keller AS; Irvin J; Taylor Z; Basu S; Ng A; Williams LM
    JAMA Netw Open; 2020 Jun; 3(6):e206653. PubMed ID: 32568399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability of frontal alpha asymmetry in depressed patients during antidepressant treatment.
    van der Vinne N; Vollebregt MA; van Putten MJAM; Arns M
    Neuroimage Clin; 2019; 24():102056. PubMed ID: 31795035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frontal and rostral anterior cingulate (rACC) theta EEG in depression: implications for treatment outcome?
    Arns M; Etkin A; Hegerl U; Williams LM; DeBattista C; Palmer DM; Fitzgerald PB; Harris A; deBeuss R; Gordon E
    Eur Neuropsychopharmacol; 2015 Aug; 25(8):1190-200. PubMed ID: 25936227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of event-related potentials in predicting antidepressant treatment response: An iSPOT-D report.
    van Dinteren R; Arns M; Kenemans L; Jongsma ML; Kessels RP; Fitzgerald P; Fallahpour K; Debattista C; Gordon E; Williams LM
    Eur Neuropsychopharmacol; 2015 Nov; 25(11):1981-90. PubMed ID: 26282359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L
    J Affect Disord; 2016 May; 196():225-33. PubMed ID: 26938965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amygdala Reactivity to Emotional Faces in the Prediction of General and Medication-Specific Responses to Antidepressant Treatment in the Randomized iSPOT-D Trial.
    Williams LM; Korgaonkar MS; Song YC; Paton R; Eagles S; Goldstein-Piekarski A; Grieve SM; Harris AW; Usherwood T; Etkin A
    Neuropsychopharmacology; 2015 Sep; 40(10):2398-408. PubMed ID: 25824424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EEG alpha asymmetry as a gender-specific predictor of outcome to acute treatment with different antidepressant medications in the randomized iSPOT-D study.
    Arns M; Bruder G; Hegerl U; Spooner C; Palmer DM; Etkin A; Fallahpour K; Gatt JM; Hirshberg L; Gordon E
    Clin Neurophysiol; 2016 Jan; 127(1):509-519. PubMed ID: 26189209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frontoparietal Activation During Response Inhibition Predicts Remission to Antidepressants in Patients With Major Depression.
    Gyurak A; Patenaude B; Korgaonkar MS; Grieve SM; Williams LM; Etkin A
    Biol Psychiatry; 2016 Feb; 79(4):274-81. PubMed ID: 25891220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine.
    Matrisciano F; Bonaccorso S; Ricciardi A; Scaccianoce S; Panaccione I; Wang L; Ruberto A; Tatarelli R; Nicoletti F; Girardi P; Shelton RC
    J Psychiatr Res; 2009 Jan; 43(3):247-54. PubMed ID: 18511076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of antidepressant treatment on cognitive impairments associated with depression: a randomised longitudinal study.
    Shilyansky C; Williams LM; Gyurak A; Harris A; Usherwood T; Etkin A
    Lancet Psychiatry; 2016 May; 3(5):425-35. PubMed ID: 26995298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heart rate variability as a biomarker of anxious depression response to antidepressant medication.
    Kircanski K; Williams LM; Gotlib IH
    Depress Anxiety; 2019 Jan; 36(1):63-71. PubMed ID: 30311742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABCB1 Genetic Effects on Antidepressant Outcomes: A Report From the iSPOT-D Trial.
    Schatzberg AF; DeBattista C; Lazzeroni LC; Etkin A; Murphy GM; Williams LM
    Am J Psychiatry; 2015 Aug; 172(8):751-9. PubMed ID: 25815420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein.
    O'Connell CP; Goldstein-Piekarski AN; Nemeroff CB; Schatzberg AF; Debattista C; Carrillo-Roa T; Binder EB; Dunlop BW; Craighead WE; Mayberg HS; Williams LM
    Am J Psychiatry; 2018 Mar; 175(3):251-261. PubMed ID: 29241359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial.
    Arnow BA; Blasey C; Williams LM; Palmer DM; Rekshan W; Schatzberg AF; Etkin A; Kulkarni J; Luther JF; Rush AJ
    Am J Psychiatry; 2015 Aug; 172(8):743-50. PubMed ID: 25815419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cognitive-emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trial.
    Etkin A; Patenaude B; Song YJ; Usherwood T; Rekshan W; Schatzberg AF; Rush AJ; Williams LM
    Neuropsychopharmacology; 2015 May; 40(6):1332-42. PubMed ID: 25547711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of antidepressant drugs in treatment of depression in children and adolescents: a network meta-analysis.
    Rao Y; Yang R; Zhao J; Cao Q
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 51(4):480-490. PubMed ID: 37202104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
    Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
    J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of nonremission to antidepressant therapy using diffusion tensor imaging.
    Grieve SM; Korgaonkar MS; Gordon E; Williams LM; Rush AJ
    J Clin Psychiatry; 2016 Apr; 77(4):e436-43. PubMed ID: 27137427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.